An interview with Andreas Grüntzig Ethica Award winner EuroPCR 2026 - Roxana Mehran

An interview with Andreas Grüntzig Ethica Award winner EuroPCR 2026 - Roxana Mehran

Nina Van Der Hoeven meets Roxana Mehran, winner of the Andreas Grüntzig Ethica Award 2026, the highest distinction in interventional cardiology. At this stage of her career, after major contributions to clinical trials, guidelines, and the field at large, Roxana Mehran reflects on her journey. What is she most proud of? How does she view clinical research today? And what key lessons has she learned along the way? In this exclusive #europcr 2026 interview, she shares her experiences, insights, and personal reflections, while also discussing the initiatives she has led since the beginning of her career to promote women in interventional cardiology. She also addresses the challenges that remain, and what still needs to be done to support and encourage more women to enter and progress in the field. Through her perspective, she reaffirms her commitment to reducing the persistent gender gap and continuing the mission she has set for herself. A conversation that highlights both a remarkable career and a continuing drive to reshape the future of the field. ---------------------------------------- Hosted on Acast. See acast.com/privacy [https://acast.com/privacy] for more information.

Long-term mortality following PCI with DES vs. CABG for left main disease

Major LBT from EuroPCR 2026 This major late-breaking trial from #EuroPCR 2026 presents a landmark patient-level meta-analysis comparing PCI with drug-eluting stents (DES) versus CABG for left main coronary artery disease. Combining long-term data from the EXCEL, NOBLE, PRECOMBAT, and SYNTAX trials, the analysis found remarkably similar mortality outcomes between the two strategies at both 5 and 10 years. David Hildick-Smith and Brian Bergmark discuss how these findings challenge traditional assumptions about the long-term survival advantage of surgery and what they mean for heart team decision-making. ---------------------------------------- Hosted on Acast. See acast.com/privacy [https://acast.com/privacy] for more information.

Coronary revascularisation in TAVI: meta-analysis of 4 Trials

Major LBTs from EuroPCR 2026 How should coronary artery disease (CAD) be managed in patients undergoing TAVI? At #europcr 2026, Martin Leon and Roberto Scarsini discuss the findings of a patient-level meta-analysis pooling data from four randomised trials: ACTIVATION, NOTION-3, FAITAVI, and TCW. The analysis included 1,050 patients with severe aortic stenosis and concomitant CAD, comparing medical therapy, angiography-guided PCI, and FFR-guided PCI strategies. At 1 year, PCI was associated with a lower rate of MACE compared with conservative management. Among the different strategies, FFR-guided PCI showed the greatest benefit, reinforcing the value of physiological assessment when treating these complex patients. Beyond the trial results, the conversation moves toward a practical algorithm for approaching severe AS and CAD, and raises important questions about when, how, and in whom revascularisation should really be performed. Listen to the full discussion to learn more about the implications of these findings for clinical practice. ---------------------------------------- Hosted on Acast. See acast.com/privacy [https://acast.com/privacy] for more information.

LAA closure vs. NOAC in patients with atrial fibrillation across age groups in the CHAMPION AF study

This major late-breaking trial from #EuroPCR 2026 highlights new insights from the CHAMPION AF study, one of the largest randomised trials comparing left atrial appendage closure (LAAC) with direct oral anticoagulants (DOACs) in patients with atrial fibrillation. In this interview, Philippe Garot and Jens Erik Nielsen-Kudsk discuss the pre-specified age subgroup analysis, showing consistent efficacy across younger and older populations, with significantly lower bleeding rates in the LAAC arm and very high procedural safety. They also explore how these findings could influence future patient selection and expand the role of LAAC in stroke prevention strategies for AF patients. ---------------------------------------- Hosted on Acast. See acast.com/privacy [https://acast.com/privacy] for more information.

What does ORBITA CTO tell us about CTO PCI?

Chronic total occlusions (CTOs) remain a key area of uncertainty in interventional cardiology, particularly regarding symptom improvement after PCI. In this EuroPCR 2026 interview, John Davies and Sarosh Khan discuss the ORBITA CTO trial and its implications for clinical practice. As the first double-blind, placebo-controlled randomised trial in CTO PCI, ORBITA CTO evaluates whether symptom relief, especially angina frequency, truly exceeds placebo in carefully selected patients. The discussion highlights the study’s design, key findings, and what they mean for CTO operators and clinicians managing patients with CTOs in everyday practice. ---------------------------------------- Hosted on Acast. See acast.com/privacy [https://acast.com/privacy] for more information.